Verastem Names John Hayslip as Chief Medical Officer

Verastem (VSTM) said late Thursday it appointed John Hayslip as chief medical officer, succeeding Louis Denis, who recently left the company. Hayslip most recently served as the chief medical officer

MT NewswiresApr 19 05:36

I-Mab Announces CMO Transition, Interim Successor Named

TipRanksApr 16 09:03

Needham: Reiterates the IMAB.US rating and adjusted from buy to buy, with a target price of $6.00.

Needham: Reiterates the IMAB.US rating and adjusted from buy to buy, with a target price of $6.00.

Zhitong FinanceApr 12 18:10

I-MAB Buy Rating Justified by Strong Leadership and Promising Pipeline

TipRanksApr 12 18:08

Needham Reiterates Buy on I-MAB, Maintains $6 Price Target

Needham analyst Gil Blum reiterates I-MAB (NASDAQ:IMAB) with a Buy and maintains $6 price target.

BenzingaApr 12 18:04

I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference

ROCKVILLE, Md., April 5, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiate

I-Mab BiopharmaApr 5 12:00